Relevant Facts (until 8 February 2020)
The Relevant facts communications included in this section correspond exactly to those submitted to the Spanish securities market regulator (CNMV) until February 8, 2020 and published on its website (www.cnmv.es).
To consult all Oryzon Genomics, S.A. registered information, please access CNMV's official registers.
-
20199 December 201925 October 20193 October 201930 September 201910 September 201930 July 201914 June 201913 May 201915 February 2019
-
20182 November 201817 October 201810 September 20187 September 201830 July 20189 May 20184 April 201819 February 2018Publication of the Company’s Annual Director Remuneration Report for year 2017 (Spanish) The Company announces changes in the composition of the Board of Directors (Spanish) The Company reports the main resolutions adopted at the Board of Directors' meeting on February 19, 2018 (Spanish) The company sends press release about 2017 Financial Results (Spanish) Corporate Governance Annual Report 2017 (Spanish) Publication of the Company‘s Results’ Information for the second semester 2017 (Spanish)
-
20177 November 201730 October 20173 October 201728 July 201720 July 20174 July 201714 June 201712 May 20179 May 20174 April 201724 February 2017Publication of the Company’s Annual Director Remuneration Report for year 2016 (Spanish) The company sends press release about 2016 Financial Results (Spanish) The Company reports the main resolutions adopted at the Board of Directors' meeting on February 23, 2017 (Spanish) Annual Corporate Governance Report 2016 (Spanish) Publication of the Company‘s Results’ Information for the second semester 2016 (Spanish)
-
201616 November 201624 October 20163 October 201626 September 20168 August 20165 July 201629 June 201612 May 201613 April 201629 February 2016Modification of the Board of Director´s Regulations and internal Code of Conduct (Spanish) Annual Corporate Governance Report 2015 (Spanish) Publication of the Company‘s Results’ Information for the second semester 2015 (Spanish) Modification of the Board of Director´s Regulations and internal Code of Conduct (Spanish) The Company reports the main resolutions adopted at the Board of Directors' meeting on February 29, 2016 (Spanish) Publication of the Company’s Annual Director Remuneration Report for year 2015 (Spanish) Approval by the Spanish Drug Agency (AEMPS) to initiate the Phase I clinical trial for ORY-2001 (Spanish) Liquidity Contract
-
201522 December 201516 December 201514 December 2015Agreement between Corporación Sant Bernat, S.L., Najeti Capital, S.A.U., D. Carlos Buesa Arjol, Oryzon Genomics, S.A., & Dña. Tamara Maes (Spanish) Agreement between Inversiones Costex, S.L., D. Carlos Buesa Arjol, Oryzon Genomics, S.A. & Dña. Tamara Maes (Spanish) Agreement between Grupo Ferrer Internacional, S.A., Najeti Capital, S.A.U., D. Carlos Buesa Arjol, Oryzon Genomics, S.A., D. José Marra Echarri Torres & Dña. Tamara Maes (Spanish) Agreement between Najeti Capital, S.A., D. Carlos Buesa Arjol Oryzon Genomics, S.A., D. José María Echarri Torres & Dña. Tamara Maes (Spanish)